TCF7L2-VTI1A Fusion FISH Probe
The TCF7L2-VTI1A Fusion FISH Probe is used to confirm a fusion of the TCF7L2 and VTI1A genes. The fusion of the TCF7L2 and VTI1A genes has been associated with Rectum Adenocarcinoma, Uterine Corpus Endometrial Carcinoma, Liver Hepatocellular Carcinoma, Liver Hepatocellular Carcinoma, Liver Hepatocellular Carcinoma, and Prostate Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
SKU | Test Kits | Buffer | Dye Color | Order Now |
---|---|---|---|---|
TCF7L2-VTI1A-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-RERE | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-REOR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-REGO | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-REGR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-REAQ | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-ORRE | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-OROR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-ORGO | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-ORAQ | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GORE | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GOOR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GOGO | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GOGR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GOAQ | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GRRE | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GROR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GRGO | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GRGR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-GRAQ | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-AQRE | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-AQOR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-AQGO | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-AQGR | 20 (40 μL) | 200 μL | ||
TCF7L2-VTI1A-20-AQAQ | 20 (40 μL) | 200 μL |
TCF7L2 Gene Summary
This gene encodes a high mobility group (HMG) box-containing transcription factor that plays a key role in the Wnt signaling pathway. The protein has been implicated in blood glucose homeostasis. Genetic variants of this gene are associated with increased risk of type 2 diabetes. Several transcript variants encoding multiple different isoforms have been found for this gene.[provided by RefSeq, Oct 2010]
Gene Name: Transcription Factor 7 Like 2
Chromosome: CHR10: 114710008 -114927436
Locus: 10q25.2-q25.3
VTI1A Gene Summary
The protein encoded by this gene is a member of the family of soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptors (SNAREs) that function in intracellular trafficking. This family member is involved in vesicular transport between endosomes and the trans-Golgi network. It is a vesicle-associated SNARE (v-SNARE) that interacts with target membrane SNAREs (t-SNAREs). Polymorphisms in this gene have been associated with binocular function, and also with susceptibility to colorectal and lung cancers. A recurrent rearrangement has been found between this gene and the transcription factor 7-like 2 (TCF7L2) gene in colorectal cancers. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
Gene Name: Vesicle Transport Through Interaction With T-SNAREs 1A
Chromosome: CHR10: 114206755 -114578504
Locus: 10q25.2
Gene Diseases
The TCF7L2 VTI1A Fusion has been associated with the following diseases:
Disease Name |
---|
Rectum Adenocarcinoma |
Uterine Corpus Endometrial Carcinoma |
Liver Hepatocellular Carcinoma |
Liver Hepatocellular Carcinoma |
Liver Hepatocellular Carcinoma |
Prostate Adenocarcinoma |
FISH Probe Protocols
Protocol, Procedure, or Form Name | Last Modified | Download |
---|